Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

June 11, 2024

https://www.globenewswire.com/news-release/2024/06/11/2896777/0/en/Processa-Pharmaceuticals-Announces-Positive-Efficacy-Results-from-Preliminary-Evaluation-of-Phase-1b-Dose-escalating-Trial-with-NGC-Cap-in-Gastrointestinal-Cancer.html

Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months

At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable disease (SD)

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.